Careers

Careers

Passionate to help us save lives?

Help for earthquake victims in Turkey

Biotest donates human albumin for earthquake victims in Turkey

In order to help those affected by the natural disaster as effectively as possible, we saw the most effective lever in providing our human albumin - a drug used in the intensive medical care of patients. Typical applications of the drug, which is derived from human blood plasma, are the treatment or prevention of shock after severe injuries, bleeding, operations, and burns.
Thanks to the good relations with our German partner, the Turkish-German Health Foundation (Türk Alman Saglik Vakfi), and the local support of the Turkish Red Crescent (Kizilay), the human albumin therapies could be delivered and distributed to emergency hospitals within the most vulnerable areas affected by the devastating earthquake.

War in Ukraine

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
CMV Hyperimmunglobulin ((CMVIG) ) - Prevention of prenatal CMV transmission
Fibrinogen (BT524) - Congenital fibrinogen deficiency
Fibrinogen (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe community acquired pneumonia
Trimodulin (BT588) - Severe COVID-19
Haemophilia A Therapeutic (HAT) - Haemophilia A

Pipeline

Pipeline

Press releases

Annual General Meeting of Biotest AG elects Raimon Grif...

09.05.2023,

09.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest’s Hyperimmunoglobulin Cytotect® CP receives fiv...

04.05.2023,

04.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest and Grifols further strengthen their cooperatio...

28.04.2023,

Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)   Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised &nbs ... [More]

Biotest AG opens 12th plasma collection centre in Hunga...

25.04.2023,

25.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest AG opens 10th plasma collection centre in Germa...

20.04.2023,

20.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest achieves important milestone in phase III trial...

30.03.2023,

30.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest core business profitable at Euro 60.7 million

23.03.2023,

23.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest donates human albumin for earthquake victims in...

14.03.2023,

14.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Preliminary announcement of the publication of financia...

28.02.2023,

28.02.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Preliminary announcement of the publication of financia...

28.02.2023,

28.02.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Biotest Supervisory Board appoints new Management Board...

10.02.2023,

10.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest significantly exceeds EBIT guidance 2022

09.02.2023,

Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)   Biotest significantly exceeds EBIT guidance 2022 Dreieich, 09 February 2023. According t ... [More]

First patient treated with Cytotect® CP Biotest in stud...

24.01.2023,

24.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest receives 'Innovation Champion of Sustainability...

19.01.2023,

19.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest treats first COVID-19 patients with trimodulin ...

10.01.2023,

10.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

First patient enrolled in phase II clinical trial for t...

08.12.2022,

08.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest reports sales of Euro 361 million in the first ...

14.11.2022,

14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest receives approval for new intravenous immunoglo...

14.11.2022,

14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest reports sales of Euro 361 million in the first ...

08.11.2022,

08.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest AG opens 14th plasma collection centre in the C...

13.10.2022,

13.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.